AMGN vs PATH · P/E 24, rev $36.75B vs P/E 19, rev $1.61B
Amgen Inc (AMGN) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
Amgen Inc (AMGN) is a drug manufacturers - general company listed on US.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported AMGN revenue for 2025-12-31 was $36.75B. Net income was $7.71B. Revenue was up 10.0% from 2024-12-31 to 2025-12-31. AMGN currently screens at market cap $188.67B and trailing P/E 24.3.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
AMGN currently screens at market cap $188.67B and trailing P/E 24.3. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the AMGN and PATH stock pages for the full models.
Not investment advice.